FY2025 EPS Estimates for Longeveron Reduced by Analyst

Longeveron Inc. (NASDAQ:LGVN) – Stock analysts at Zacks Small Cap cut their FY2025 EPS estimates for Longeveron in a report released on Monday, March 3rd. Zacks Small Cap analyst B. Sorensen now anticipates that the company will earn ($1.84) per share for the year, down from their previous estimate of ($1.28). The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

Other research analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Longeveron in a report on Monday. Roth Capital upgraded Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Roth Mkm began coverage on shares of Longeveron in a research report on Friday, December 6th. They issued a “buy” rating and a $10.00 price target for the company.

Longeveron Price Performance

Shares of LGVN opened at $1.40 on Wednesday. Longeveron has a one year low of $0.77 and a one year high of $6.40. The company has a market cap of $20.77 million, a PE ratio of -0.22 and a beta of 0.36. The stock has a 50-day moving average of $1.64 and a 200-day moving average of $1.89.

Institutional Trading of Longeveron

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its holdings in Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after buying an additional 97,953 shares in the last quarter. Virtu Financial LLC purchased a new position in Longeveron during the 4th quarter worth $53,000. Jane Street Group LLC bought a new stake in shares of Longeveron in the 4th quarter worth $35,000. Northern Trust Corp purchased a new stake in shares of Longeveron in the fourth quarter valued at about $31,000. Finally, State Street Corp bought a new position in shares of Longeveron during the third quarter valued at about $29,000. 10.01% of the stock is owned by hedge funds and other institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.